CBPO on NASDAQ

China Biologic Products, Inc.

Chinese pharmaceutical company

China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is the only blood plasma-based biopharmaceutical company approved by the government of Shandong Province.³ Its shares trade on NASDAQ under the symbol CBPO.¹ Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

TickerCBPO on NASDAQ¹
Industrybiotechnology¹
HeadquartersBeijing¹
Websitechinabiologic.com
Business address18Th Fl, Jialong Internationalbuilding, 19 Chaoyang Park Road, Chaoyang District, Beijing, F4 100125⁴
Filer categoryLarge accelerated filer⁴

See how the biggest companies compare on our leaderboards

Corporate structure

China Biologic Products, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of China Biologic Products, Inc.

Parfield International Ltd Filed SC 13D/A on China Biologic Products, Inc., latest May 12, 2023

China Biologic Products, Inc. Beijing

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What China Biologic Products, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Construction in progress	$7.7M⁶ Dec 31, 2018	$105.2M⁶ Dec 31, 2017	−92.7%
Property and equipment, before depreciation	$236.0M⁷ Dec 31, 2019	$218.1M⁷ Dec 31, 2018	+8.2%
Accumulated depreciation	$58.5M⁷ Dec 31, 2019	$42.4M⁷ Dec 31, 2018	+37.7%
Property and equipment, net	$177.6M⁷ Dec 31, 2019	$178.3M⁷ Dec 31, 2018	−0.4%
Operating-lease assets (leased space)	$5.6M⁷ Dec 31, 2019

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$161.8M⁷ Dec 31, 2019	$338.9M⁷ Dec 31, 2018	−52.3%
Marketable securities, current	$76.0M⁶ Dec 31, 2018	$0⁶ Dec 31, 2017
Stakes in other companies (equity method)	$16.7M⁷ Dec 31, 2019	$15.4M⁷ Dec 31, 2018	+8.4%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$308.5M⁷ Dec 31, 2019	$313.6M⁷ Dec 31, 2018	−1.6%
Intangible assets, net (excluding goodwill)	$44.1M⁷ Dec 31, 2019	$53.3M⁷ Dec 31, 2018	−17.3%
Accumulated amortization	$20.5M⁷ Dec 31, 2019	$13.0M⁷ Dec 31, 2018	+57.0%
Finite-lived intangibles, net	$39.8M⁷ Dec 31, 2019	$40.5M⁶ Dec 31, 2018	−1.8%

Inventory

Item	Latest	A year before	Change
Inventory, total	$250.7M⁷ Dec 31, 2019	$243.3M⁷ Dec 31, 2018	+3.1%
Work in process	$75.4M⁷ Dec 31, 2019	$57.5M⁷ Dec 31, 2018	+31.3%
Finished goods	$68.5M⁷ Dec 31, 2019	$61.4M⁷ Dec 31, 2018	+11.5%

The story

The company is engaged in the research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China. Plasma-based human albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.

Previously listed on Nasdaq, in April 2021, it was taken private in a $4.6 billion deal by an investor group that included Centurium Capital, CITIC Capital and Hillhouse Capital.

From Wikipedia’s article on China Biologic Products, shared under CC BY-SA 4.0.⁵

Leadership

Who has led China Biologic Products, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chao Ming Zhao2012

Chief financial officer

2010201520202025

Chief executive officerDavid Gao May 14, 2012 to Mar 2, 2017⁸
Chief executive officerChao Ming Zhao Dec 14, 2009 to Sep 9, 2010⁹
Chief executive officerCbpo Stanley Wong Sep 13, 2007 to May 16, 2008¹⁰
PresidentChao Ming Zhao Nov 30, 2012 to Nov 30, 2012¹¹
Chief financial officerYuyun Tristan Kuo Jun 5, 2008 to Dec 14, 2011¹²
Chief financial officerChao Ming Zhao Sep 12, 2007 to May 16, 2008¹³

Board members and other officers (22)

Vice PresidentZhijing Cbpo Liu Apr 29, 2013 to May 10, 2017¹⁴
Corporate Vice PresidentGang Cbpo Yang Aug 26, 2013 to Aug 17, 2016¹⁵
DCTR CONTROLLING SHAREHOLDERLing Siu Chan Sep 12, 2007 to Sep 12, 2007¹⁶
Board memberMin Fang Mar 12, 2015 to Aug 12, 2016¹⁷
Board memberDai Feng May 9, 2014 to May 9, 2014¹⁸
Board memberYungang Lu Mar 23, 2012 to Aug 8, 2016¹⁹
Board memberHan Zhang Apr 30, 2012 to Apr 30, 2012²⁰
Board memberZhijun Tong Apr 30, 2012 to Aug 8, 2016²¹
Board memberLe Zhang Oct 1, 2012 to Aug 20, 2013²²
Board memberChong Yang Li Jan 28, 2011 to Jan 28, 2011²³
Board memberWenfang Liu Mar 18, 2011 to Aug 17, 2016²⁴
Board memberPincus X. L.p. Warburg May 24, 2011 to Jun 8, 2016²⁵
Board memberDavid Gao Nov 15, 2011 to Mar 2, 2017²⁶
Board memberJoseph Landy Dec 1, 2011 to May 15, 2013²⁷
Board memberXiangmin Cui Mar 26, 2010 to Jan 28, 2011²⁸
Board memberGuang Li Pang May 16, 2008 to May 16, 2008²⁹
Board memberLin Ling Li May 16, 2008 to Dec 14, 2010³⁰
Board memberSean Shao Aug 18, 2008 to Mar 3, 2017³¹
Board memberTong Jun Lin Aug 20, 2008 to Jan 28, 2011³²
Board memberJie Gan Sep 10, 2008 to Sep 10, 2008³³
Board memberChao Ming Zhao Sep 12, 2007 to Jun 29, 2010¹³
Board memberLing Siu Chan Sep 12, 2007 to Dec 14, 2010¹⁶

Timeline

May 14, 2012New chief executive David Gao becomes CEO⁸
Dec 14, 2009New chief executive Chao Ming Zhao becomes CEO⁹
Sep 13, 2007New chief executive Cbpo Stanley Wong becomes CEO¹⁰
Apr 3, 2007Went public Listed on NASDAQ¹

Filings

3 filings to the SEC since October 2021: 1 large holders, 2 other. The latest 3:

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Parfield International LtdSC 13D/A, 1 filing May 12, 2023³⁴

SEC filer profile

How China Biologic Products, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARChina Biologic Products Holdings, Inc.²
CIK0001369868
Employer ID (EIN)75-2308816²
Filer statusLarge accelerated filer²
Fiscal year endsDecember 31²
Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)²
Business address18Th Fl, Jialong Internationalbuilding, 19 Chaoyang Park Road, Chaoyang District, Beijing, F4 100125²
Phone86-10-6598-3111²
Shares outstanding38,459,769 as of Dec 31, 2019⁷
On EDGAR sinceSep 5, 2007²
Filings719 in all: 4 (148), 8-K (147), SC 13D/A (99), 6-K (53), 10-Q (29), 3 (29), SC 13G/A (23), SC 13G (18)²
All 52 form types
SC 13D (15), UPLOAD (14), 10-K/A (11), 10-K (9), CORRESP (9), SC 13E3/A (9), 424B7 (8), DEF 14A (8), DEFA14A (8), IRANNOTICE (8), 10-Q/A (7), EFFECT (5), 424B5 (4), 8-A12B (4), 8-K/A (4), S-1/A (4), 20-F (3), FWP (3), PRER14A (3), S-3 (3), S-8 POS (3), SB-2/A (3), 15-12B (2), 25-NSE (2), 8-A12B/A (2), CT ORDER (2), DEFR14A (2), S-8 (2), 10KSB (1), 10QSB (1), 4/A (1), 424B3 (1), 424B4 (1), 425 (1), 8-A12G (1), 8-K12B (1), CERTNAS (1), D (1), NT 10-K (1), NT 10-Q (1), S-1 (1), S-3/A (1), S-3ASR (1), SB-2 (1)
Latest filingsAnnual report (20-F) Mar 12, 2020
Quarterly report (10-Q) Aug 2, 2017
Proxy statement (DEF 14A) May 19, 2017
Latest 8-K (8-K) Jul 21, 2017

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataChina Biologic Products, Inc. on Wikidata
2
SEC EDGARChina Biologic Products, Inc. filings on SEC EDGAR
3
WikipediaChina Biologic Products, Inc. on Wikipedia
4
SEC EDGARChina Biologic Products, Inc. filings on SEC EDGAR
5
WikipediaChina Biologic Products, Inc. on Wikipedia (revision used)
6
SEC EDGARChina Biologic Products, Inc. 20-F for fiscal 2018
7
SEC EDGARChina Biologic Products, Inc. 20-F for fiscal 2019
8
SEC EDGARDavid Gao, Chief executive officer
9
SEC EDGARChao Ming Zhao, Chief executive officer
10
SEC EDGARCbpo Stanley Wong, Chief executive officer
11
SEC EDGARChao Ming Zhao, President
12
SEC EDGARYuyun Tristan Kuo, Chief financial officer
13
SEC EDGARChao Ming Zhao, Chief financial officer
14
SEC EDGARZhijing Cbpo Liu, Vice President
15
SEC EDGARGang Cbpo Yang, Corporate Vice President
16
SEC EDGARLing Siu Chan, DCTR CONTROLLING SHAREHOLDER
17
SEC EDGARMin Fang, Board member
18
SEC EDGARDai Feng, Board member
19
SEC EDGARYungang Lu, Board member
20
SEC EDGARHan Zhang, Board member
21
SEC EDGARZhijun Tong, Board member
22
SEC EDGARLe Zhang, Board member
23
SEC EDGARChong Yang Li, Board member
24
SEC EDGARWenfang Liu, Board member
25
SEC EDGARPincus X. L.p. Warburg, Board member
26
SEC EDGARDavid Gao, Board member
27
SEC EDGARJoseph Landy, Board member
28
SEC EDGARXiangmin Cui, Board member
29
SEC EDGARGuang Li Pang, Board member
30
SEC EDGARLin Ling Li, Board member
31
SEC EDGARSean Shao, Board member
32
SEC EDGARTong Jun Lin, Board member
33
SEC EDGARJie Gan, Board member
34
SEC EDGARParfield International Ltd SC 13D/A on China Biologic Products, Inc.